SGLT2 Inhibitors Poised to Potentially Reshape Chronic Kidney Disease (CKD) and Diabetic Kidney Disease (DKD) Patient Care After AstraZeneca’s Farxiga Approval
According to new research from Spherix Global Insights, the FDA approval of Farxiga is likely to ignite a shift towards